- Home
- CTNM vs MRVI Comparison
CTNM vs MRVI Comparison
Compare CTNM & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTNM
- MRVI
- Stock Information
- Founded
- CTNM 2009
- MRVI 2014
- Country
- CTNM United States
- MRVI United States
- Employees
- CTNM N/A
- MRVI N/A
- Industry
- CTNM
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- CTNM
- MRVI Health Care
- Exchange
- CTNM Nasdaq
- MRVI Nasdaq
- Market Cap
- CTNM 328.1M
- MRVI 376.2M
- IPO Year
- CTNM 2024
- MRVI 2020
- Fundamental
- Price
- CTNM $11.01
- MRVI $3.14
- Analyst Decision
- CTNM Strong Buy
- MRVI Hold
- Analyst Count
- CTNM 5
- MRVI 9
- Target Price
- CTNM $22.20
- MRVI $4.54
- AVG Volume (30 Days)
- CTNM 92.7K
- MRVI 1.7M
- Earning Date
- CTNM 10-30-2025
- MRVI 11-06-2025
- Dividend Yield
- CTNM N/A
- MRVI N/A
- EPS Growth
- CTNM N/A
- MRVI N/A
- EPS
- CTNM N/A
- MRVI N/A
- Revenue
- CTNM N/A
- MRVI $219,830,000.00
- Revenue This Year
- CTNM N/A
- MRVI N/A
- Revenue Next Year
- CTNM N/A
- MRVI $7.27
- P/E Ratio
- CTNM N/A
- MRVI N/A
- Revenue Growth
- CTNM N/A
- MRVI N/A
- 52 Week Low
- CTNM $3.35
- MRVI $1.67
- 52 Week High
- CTNM $20.24
- MRVI $8.29
- Technical
- Relative Strength Index (RSI)
- CTNM 48.88
- MRVI 48.93
- Support Level
- CTNM $10.77
- MRVI $3.01
- Resistance Level
- CTNM $11.34
- MRVI $3.55
- Average True Range (ATR)
- CTNM 0.68
- MRVI 0.19
- MACD
- CTNM -0.15
- MRVI -0.06
- Stochastic Oscillator
- CTNM 31.37
- MRVI 20.31
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.